NCT04556981 Safety and Immunogenicity of M72/AS01E in Participants With Well-controlled HIV (MESA-TB)

DISCLAIMER – FOR INFORMATIONAL PURPOSES ONLY; USE AT YOUR OWN RISK

The protocol content here is for informational purposes only and does not constitute legal, medical, clinical, or safety advice, or otherwise; content added to protocols.io is not peer reviewed and may not have undergone a formal approval of any kind. Information presented in this protocol should not substitute for independent professional judgment, advice, diagnosis, or treatment. Any action you take or refrain from taking using or relying upon the information presented here is strictly at your own risk. You agree that neither the Company nor any of the authors, contributors, administrators, or anyone else associated with protocols.io, can be held responsible for your use of the information contained in or linked to this protocol or any of our Sites/Apps and Services.

Protocol Title: A randomized, placebo-controlled, observer-blind, phase 2 study to evaluate

safety and immunogenicity of the investigational M72/AS01E Mycobacterium tuberculosis (Mtb)

vaccine in virally suppressed, antiretroviral-treated participants with human immunodeficiency

virus (HIV)

Short Title: Safety and immunogenicity of a TB vaccine M72/AS01E in participants with well controlled

HIV

Rationale:

Published phase 1 and 2 randomized, controlled trials evaluating M72/AS01E vaccination in

individuals with HIV who were receiving antiretroviral therapy (ART) show that a 2-dose

schedule of the vaccine given one month apart is well-tolerated and immunogenic in this

population. This current study intends to confirm that the vaccine is safe, well-tolerated, and

immunogenic in a larger population of people with virally suppressed HIV infection in a

tuberculosis (TB) endemic region.

NCT04556981 Protocol Version 3.0_Redacted.pdf